Is Amylyx Pharmaceuticals, Inc. (AMLX) a Buy, Sell, or Hold?
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$18.2 USD
$0.79 (4.54%)
- Volume
- 2.02M
- Average Volume
- 1.35M
- Market Capitalization
- $1.51B
- P/E Ratio
- -12.30
- Dividend Yield
- 0.00%
- Price Target
- $34.00
- Year High
- $19.15
- Year Low
- $7.48
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $17.85
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Joshua Cohen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AMLX |
| CUSIP | 03237H101 |
| CIK | 0001658551 |
| Web | https://amylyx.com |
| Phone | 617 682 0917 |
| Currency | USD |
| Employees | 136 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 17.85 |
| Quick Ratio | 17.85 |
| Cash Ratio | 14.35 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.09 |
| Price / Cash Flow | -12.55 |
| Price / Book | 7.37 |
Price Target and Rating
| Average Stock Price Forecast | $34.00 |
| High Stock Price Forecast | $40.00 |
| Low Stock Price Forecast | $21.00 |
| Forecast Upside/Downside | -46.47% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.53 |
| Trailing P/E Ratio | -12.30 |
| PEG Ratio | -0.15 |
| P/E Growth | -0.15 |
| Net Income | $-144.74M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -55.69% |
| Return on Assets | -51.13% |
Financials Score
| AltmanZ Score | 37.84 |
| Piotroski Score | 3.00 |
| Working Capital | 269.06M |
| Total Assets | 293.6M |
| Ebit | -148.17M |
| Market Cap | 1.44B |
| Total Liabilities | 20.44M |
Poll Results
About Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts. ...
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
2026-07-03 12:15:00
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
2026-06-23 07:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026.
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
2026-06-10 18:13:38
Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
2026-06-10 13:52:16
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
2026-06-08 10:00:00
[url="]Amylyx Pharmaceuticals, Inc.[/url] (NASDAQ: AMLX) (âAmylyxâ or the âCompanyâ) today announced two poster presentations at the upcoming Endocrine
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
2026-06-08 09:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026.
2026-06-08 08:00:00
BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of publicly traded securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX): SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION To: All those who purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx”) securities between November 11, 2022, and November 8, 2023, inclusive (the “Class Period”), and who were allegedly damaged thereby (the “Settlement Class”). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts, that Plaintiff Oliver Shih, on behalf of himself and all members of the proposed Settlement Class, and Amylyx, Joshua B.
2026-05-15 12:11:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal. The publication reports Week 24 and Week 48 results from the Phase 2 ope.
Frequently Asked Questions
-
What is the current Amylyx Pharmaceuticals, Inc. (AMLX) stock price?
-
Amylyx Pharmaceuticals, Inc.(NASDAQ:AMLX) stock price is $18.2 in the last trading session. During the trading session, AMLX stock reached the peak price of $19.15 while $7.48 was the lowest point it dropped to. The percentage change in AMLX stock occurred in the recent session was 4.54% while the dollar amount for the price change in AMLX stock was $0.79.
-
AMLX's industry and sector of operation?
-
The NASDAQ listed AMLX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AMLX?
-
Justin Klee | Co-CEO & Director
Gina Mazzariello | Chief Legal Officer & General Counsel
Jamie Timmons | Head of Global Medical Strategy & Communications
Machelle Manuel | Vice President & Head of Global Medical Affairs
Tom Holmes | Chief Technical Operations Officer -
How many employees does AMLX have?
-
Number of AMLX employees currently stands at 136. AMLX operates from 43 Thorndike Street, Cambridge, MA 02141, US.
-
Link for AMLX official website?
-
Official Website of AMLX is: https://amylyx.com
-
How do I contact AMLX?
-
AMLX could be contacted at phone #617 682 0917 and can also be accessed through its website. AMLX operates from 43 Thorndike Street, Cambridge, MA 02141, US.
-
How many shares of AMLX are traded daily?
-
The average number of AMLX shares traded daily for last 3 months was 1.35M.
-
What is the market cap of AMLX currently?
-
The market value of AMLX currently stands at $1.51B with its latest stock price at $18.2